Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth R Chapman

Showing results (41-50 of 176) with videos related to

Pageof 18
Sort By:
Canadian Respiratory Journal|December 22, 2011
Mortality among subjects with chronic obstructive pulmonary disease or asthma at two respiratory disease clinics in OntarioMurray M Finkelstein, Kenneth R Chapman, R Andrew McIvor, et al.
Canadian Respiratory Journal|August 16, 2006
The role of omalizumab in the treatment of severe allergic asthmaKenneth R Chapman, Andre Cartier, Jacques Hébert, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|April 12, 2013
What do we know about asthma triggers? a review of the literatureMargaret K Vernon, Ingela Wiklund, Jill A Bell, et al.
The Journal of Allergy and Clinical Immunology|February 18, 2003
Effect of nasal triamcinolone acetonide on lower airway inflammatory markers in patients with allergic rhinitisAlessandra Sandrini, Ivone M Ferreira, Jose R Jardim, et al.
Chest|February 26, 2011
Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled studyKenneth R Chapman, Stephen I Rennard, Angeli Dogra, et al.
Thorax|June 29, 2010
Single maintenance and reliever therapy (SMART) of asthma: a critical appraisalKenneth R Chapman, Neil C Barnes, Andrew P Greening, et al.
Expert Review of Respiratory Medicine|June 17, 2021
Aclidinium bromide/formoterol fumarate as a treatment for COPD: an updateAnthony D D'Urzo, Dave Singh, James F Donohue, et al.
International Journal of Chronic Obstructive Pulmonary Disease|February 13, 2018
Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implicationsKenneth R Chapman, Joanna Chorostowska-Wynimko, A Rembert Koczulla, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|August 30, 2017
QVA149 Improves Lung Function, Dyspnea, and Health Status Independent of Previously Prescribed Medications and COPD Severity: A Subgroup Analysis from the SHINE and ILLUMINATE StudiesKenneth R Chapman, Eric D Bateman, Hungta Chen, et al.
The Journal of Allergy and Clinical Immunology|July 9, 2003
Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalersHarold S Nelson, Kenneth R Chapman, Stephen D Pyke, et al.
Pageof 18

Showing results (41-50 of 176) with videos related to

Sort By:
Pageof 18
Canadian Respiratory Journal|December 22, 2011
Mortality among subjects with chronic obstructive pulmonary disease or asthma at two respiratory disease clinics in OntarioMurray M Finkelstein, Kenneth R Chapman, R Andrew McIvor, et al.
Canadian Respiratory Journal|August 16, 2006
The role of omalizumab in the treatment of severe allergic asthmaKenneth R Chapman, Andre Cartier, Jacques Hébert, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|April 12, 2013
What do we know about asthma triggers? a review of the literatureMargaret K Vernon, Ingela Wiklund, Jill A Bell, et al.
The Journal of Allergy and Clinical Immunology|February 18, 2003
Effect of nasal triamcinolone acetonide on lower airway inflammatory markers in patients with allergic rhinitisAlessandra Sandrini, Ivone M Ferreira, Jose R Jardim, et al.
Chest|February 26, 2011
Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled studyKenneth R Chapman, Stephen I Rennard, Angeli Dogra, et al.
Thorax|June 29, 2010
Single maintenance and reliever therapy (SMART) of asthma: a critical appraisalKenneth R Chapman, Neil C Barnes, Andrew P Greening, et al.
Expert Review of Respiratory Medicine|June 17, 2021
Aclidinium bromide/formoterol fumarate as a treatment for COPD: an updateAnthony D D'Urzo, Dave Singh, James F Donohue, et al.
International Journal of Chronic Obstructive Pulmonary Disease|February 13, 2018
Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implicationsKenneth R Chapman, Joanna Chorostowska-Wynimko, A Rembert Koczulla, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|August 30, 2017
QVA149 Improves Lung Function, Dyspnea, and Health Status Independent of Previously Prescribed Medications and COPD Severity: A Subgroup Analysis from the SHINE and ILLUMINATE StudiesKenneth R Chapman, Eric D Bateman, Hungta Chen, et al.
The Journal of Allergy and Clinical Immunology|July 9, 2003
Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalersHarold S Nelson, Kenneth R Chapman, Stephen D Pyke, et al.
Pageof 18